Generate Biomedicines (GENB) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Trevi Therapeutics is the larger company by market cap ($1.83 billion vs $1.80 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GENB | TRVI |
|---|---|---|
| Share price | $13.99 | $12.83 |
| Market cap | $1.80B | $1.83B |
| 1-day change | +3.10% | -2.40% |
| YTD return | — | +2.44% |
| 1-year return | — | +30.60% |
| 5-year return | — | +918.60% |
| EPS (TTM) | $-2.44 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.67 | $20.22 |
| 52-week low | $11.00 | $9.28 |
| Distance from 52-week high | -38.29% | -36.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +92.99% | +119.73% |
| Average volume | 1.05M | 1.95M |
| Shares outstanding | 128.35M | 142.48M |
| Employees | 312 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
GENB vs TRVI FAQ
Which is bigger, Generate Biomedicines or Trevi Therapeutics?
Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.83B compared with $1.80B for Generate Biomedicines (GENB).
Are Generate Biomedicines and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.